{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:22:33Z","timestamp":1787156553857,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R01HD102545-01A1"],"award-info":[{"award-number":["1R01HD102545-01A1"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003402","name":"Fundaci\u00f3n Valle del Lili","doi-asserted-by":"publisher","award":["2025-ART-001"],"award-info":[{"award-number":["2025-ART-001"]}],"id":[{"id":"10.13039\/501100003402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022778","name":"Carol Ann Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018298","name":"Bennett Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002411","name":"Universidad ICESI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymgme.2025.109255","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:53:47Z","timestamp":1759798427000},"page":"109255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mucopolysaccharidosis VI: Therapeutic trategies and erspectives"],"prefix":"10.1016","volume":"146","author":[{"given":"Andr\u00e9s Felipe","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Eduardo","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Pachajoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ymgme.2025.109255_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413456","article-title":"Mucopolysaccharidosis type VI, an updated overview of the disease","volume":"22","author":"D\u2019Avanzo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109255_bb0010","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2147\/OPTH.S78368","article-title":"Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses","volume":"9","author":"Fenzl","year":"2015","journal-title":"Clin. Ophthalmol."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109255_bb0015","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/humu.23613","article-title":"Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: review and classification of published variants in the ARSB gene","volume":"39","author":"Tomanin","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2025.109255_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109255_bb0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2741\/4490","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"22","author":"Harmatz","year":"2017","journal-title":"Front Biosci (Landmark Ed)."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021113","article-title":"Molecular mechanisms in pathophysiology of Mucopolysaccharidosis and prospects for innovative therapy","volume":"25","author":"Ago","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"Involvement of the toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0040","first-page":"85","article-title":"Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation","volume":"3","author":"Simonaro","year":"2010","journal-title":"J. Pediatr. Rehabil. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2353\/ajpath.2008.070564","article-title":"Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases","volume":"172","author":"Simonaro","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2025.109255_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.998039","article-title":"Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI","volume":"13","author":"Nagpal","year":"2022","journal-title":"Front. Physiol."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109255_bb0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200052","article-title":"Liver-directed adeno-associated virus-mediated gene therapy for Mucopolysaccharidosis type VI","volume":"1","author":"Brunetti-Pierri","year":"2022","journal-title":"NEJM Evid."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109255_bb0060","article-title":"Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI","volume":"9","author":"Brunelli","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2021.02.006","article-title":"Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: a resurvey study","volume":"133","author":"Horovitz","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109255_bb0070","article-title":"Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models","volume":"37","author":"Tuyaa-Boustugue","year":"2023","journal-title":"Mol Genet Metab Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jimd.12467","article-title":"Oral treatment for mucopolysaccharidosis VI: outcomes of the first phase IIa study with odiparcil","volume":"45","author":"Guffon","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109255_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233032","article-title":"Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-evidence from in vitro and in vivo models","volume":"15","author":"Entchev","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10545-012-9521-y","article-title":"Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI","volume":"36","author":"Bartolomeo","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13256-021-03240-3","article-title":"Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report","volume":"16","author":"Andrade","year":"2022","journal-title":"J. Med. Case Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2021.03.006","article-title":"Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy","volume":"133","author":"Garcia","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109255_bb0100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/0929867328666210526144654","article-title":"Enzyme replacement therapy for genetic disorders associated with enzyme deficiency","volume":"29","author":"Marchetti","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-021-01675-x","article-title":"Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a managed access agreement in England","volume":"16","author":"Cleary","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0110","first-page":"104","article-title":"Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes","volume":"58","author":"Politei","year":"2021","journal-title":"JIMD Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109255_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","article-title":"Effect of enzyme replacement therapy on the growth of patients with Morquio a","volume":"64","author":"Doherty","year":"2019","journal-title":"J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109255_bb0120","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/21678707.2015.1086640","article-title":"Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio a syndrome): effect and limitations","volume":"3","author":"Tomatsu","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"issue":"13","key":"10.1016\/j.ymgme.2025.109255_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26136448","article-title":"Mesenchymal stem cell-derived extracellular vesicles: seeking into cell-free therapies for bone-affected lysosomal storage disorders","volume":"26","author":"Leal","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.ymgme.2025.109255_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158339","article-title":"Potential targeting mechanisms for bone-directed therapies","volume":"25","author":"Celik","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.ymgme.2025.109255_bb0135","doi-asserted-by":"crossref","first-page":"9348","DOI":"10.1039\/D2NR04971F","article-title":"Defect-free graphene enhances enzyme delivery to fibroblasts derived from patients with lysosomal storage disorders","volume":"15","author":"Chen","year":"2023","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40820-021-00670-y","article-title":"Nanoparticle-cartilage interaction: pathology-based intra-articular drug delivery for osteoarthritis therapy","volume":"13","author":"Li","year":"2021","journal-title":"Nano Lett."},{"issue":"4 Pt 1","key":"10.1016\/j.ymgme.2025.109255_bb0145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1203\/01.pdr.0000203090.41012.a6","article-title":"Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval","volume":"59","author":"Auclair","year":"2006","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109255_bb0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymgme.2007.04.009","article-title":"Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI","volume":"91","author":"Auclair","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109255_bb0155","article-title":"Septic arthritis following joint injections: a 17 years retrospective study in an academic general hospital","volume":"92","author":"Larghi","year":"2022","journal-title":"Acta Biomed"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109255_bb0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2014.05.015","article-title":"Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I","volume":"112","author":"Wang","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"19","key":"10.1016\/j.ymgme.2025.109255_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911168","article-title":"MPSI manifestations and treatment outcome: skeletal focus","volume":"23","author":"De Ponti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10545-015-9900-2","article-title":"Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?","volume":"39","author":"Tomatsu","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ymgme.2014.05.013","article-title":"Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"21","key":"10.1016\/j.ymgme.2025.109255_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171312","article-title":"Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal development","volume":"8","author":"Hwang-Wong","year":"2023","journal-title":"JCI Insight"},{"issue":"34","key":"10.1016\/j.ymgme.2025.109255_bb0185","doi-asserted-by":"crossref","first-page":"E3179","DOI":"10.1073\/pnas.1217812110","article-title":"Conditionals by inversion provide a universal method for the generation of conditional alleles","volume":"110","author":"Economides","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2025.109255_bb0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.omtm.2017.07.004","article-title":"Non-clinical safety and efficacy of an AAV2\/8 vector administered intravenously for treatment of Mucopolysaccharidosis type VI","volume":"6","author":"Ferla","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109255_bb0195","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/mt.2016.181","article-title":"Low-dose gene therapy reduces the frequency of enzyme replacement therapy in a mouse model of lysosomal storage disease","volume":"24","author":"Alliegro","year":"2016","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109255_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.10.021","article-title":"Multi-year enzyme expression in patients with mucopolysaccharidosis type VI after liver-directed gene therapy","volume":"6","author":"Rossi","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106968","article-title":"The landscape of CRISPR\/Cas9 for inborn errors of metabolism","volume":"138","author":"Leal","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010477","article-title":"Mucopolysaccharidoses: cellular consequences of Glycosaminoglycans accumulation and potential targets","volume":"24","author":"Leal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109255_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052456","article-title":"Current strategies for increasing Knock-in efficiency in CRISPR\/Cas9-based approaches","volume":"25","author":"Leal","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102138","article-title":"Recent advances in CRISPR-Cas9-based genome insertion technologies","volume":"35","author":"Chen","year":"2024","journal-title":"Mol Ther Nucleic Acids."},{"issue":"6629","key":"10.1016\/j.ymgme.2025.109255_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2025.109255_bb0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.ymgme.2025.109255_bb0235","article-title":"Generation of a novel disease model mouse for mucopolysaccharidosis type VI via c. 252T>C human","volume":"31","author":"Hosoba","year":"2022","journal-title":"Biochem Biophys Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109255_bb0240","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymgme.2011.08.029","article-title":"Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI","volume":"104","author":"Furujo","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109255_bb0245","article-title":"CRISPR\/Cas9 technology in the modeling of and treatment of mucopolysaccharidosis","volume":"39","author":"Reyhani-Ardabili","year":"2024","journal-title":"Biochem Biophys Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109255_bb0250","article-title":"Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases","volume":"5","author":"Esposito","year":"2024","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.ymgme.2025.109255_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2023.101153","article-title":"Iron oxide-coupled CRISPR\/nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice","volume":"31","author":"Leal","year":"2023","journal-title":"Mol. Ther. Meth. Clin. Develop."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0260","doi-asserted-by":"crossref","first-page":"15045","DOI":"10.1038\/s41598-022-19407-x","article-title":"Delivery and assessment of a CRISPR\/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles","volume":"12","author":"Leal","year":"2022","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109255_bb0265","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.hoc.2022.03.012","article-title":"Ex vivo and in vivo gene therapy for Mucopolysaccharidoses: state of the art","volume":"36","author":"Consiglieri","year":"2022","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109255_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for Mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2025.109255_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.877735","article-title":"The outcome of allogeneic hematopoietic stem cell transplantation from different donors in recipients with Mucopolysaccharidosis","volume":"10","author":"Qu","year":"2022","journal-title":"Front. Pediatr."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109255_bb0280","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3345\/cep.2024.02033","article-title":"Hematopoietic stem cell transplantation in pediatric patients with type VI mucopolysaccharidosis","volume":"68","author":"Uygun","year":"2025","journal-title":"Clin. Exp. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109255_bb0285","article-title":"Successful combined umbilical cord blood and bone marrow transplantation from an HLA-matched sibling for MPS VI: a case report","volume":"4","author":"Haria","year":"2023","journal-title":"Ther Adv Rare Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109255_bb0290","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of Mucopolysaccharidosis-a ten-year report from the China children transplant group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13052-025-01919-7","article-title":"Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: a single-center experience and assessment of quality of life","volume":"51","author":"Zhang","year":"2025","journal-title":"Ital. J. Pediatr."},{"issue":"18","key":"10.1016\/j.ymgme.2025.109255_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181524","article-title":"Current approaches for the prevention and treatment of acute and chronic GVHD","volume":"13","author":"Olivieri","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0310","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jimd.12626","article-title":"Gene therapies for mucopolysaccharidoses","volume":"47","author":"Rossi","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109255_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26094334","article-title":"CRISPR\/nCas9-edited CD34+ cells rescue Mucopolysaccharidosis IVA fibroblasts phenotype","volume":"26","author":"Herreno-Pach\u00f3n","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109255_bb0320","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.omtm.2022.04.009","article-title":"Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation","volume":"25","author":"Poletto","year":"2022","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"21\u221222","key":"10.1016\/j.ymgme.2025.109255_bb0325","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/hum.2024.094","article-title":"Lentiviral vector-mediated ex vivo hematopoietic stem cell gene therapy for Mucopolysaccharidosis IVA murine model","volume":"35","author":"Celik","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0330","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-019-11962-8","article-title":"Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I","volume":"10","author":"Gomez-Ospina","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2025.109255_bb0335","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00109-020-01935-6","article-title":"Lysosomal storage diseases: current therapies and future alternatives","author":"Leal","year":"2020","journal-title":"J. Mol. Med. (Berl)"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109255_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022447","article-title":"Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI","volume":"6","author":"Eliyahu","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054459","article-title":"Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses","volume":"8","author":"Schuchman","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109255_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100882","article-title":"Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment","volume":"9","author":"Frohbergh","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109255_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135873","article-title":"Evaluation of aminoglycoside and non-aminoglycoside compounds for stop-codon Readthrough therapy in four lysosomal storage diseases","volume":"10","author":"G\u00f3mez-Grau","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109255_bb0360","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.xphs.2024.02.006","article-title":"Stop-codon Readthrough in therapeutic protein candidates expressed from mammalian cells","volume":"113","author":"Zhang","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"10101","key":"10.1016\/j.ymgme.2025.109255_bb0365","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-8417-2-4","article-title":"Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI","volume":"2","author":"Tessitore","year":"2009","journal-title":"Pathogenetics"},{"key":"10.1016\/j.ymgme.2025.109255_bb0380","doi-asserted-by":"crossref","first-page":"34140","DOI":"10.1038\/s41598-025-04871-y","article-title":"Three-dimensional human mucopolysaccharidosis IVA chondrocyte culture reveals significant impairments in the lysosomal-mitochondrial crosstalk","volume":"15","author":"Leal","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109255_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70065","article-title":"Therapies for mitochondrial disease: past, present, and future","volume":"48","author":"Ball","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"issue":"10322","key":"10.1016\/j.ymgme.2025.109255_bb0390","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ymgme.2025.109255_bb0395","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109255_bb0400","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/ijms21010232","article-title":"Advances in the development of pharmacological chaperones for the mucopolysaccharidoses","volume":"21","author":"Losada D\u00edaz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109255_bb0405","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/TACG.S206076","article-title":"GM1 Gangliosidosis: mechanisms and management","volume":"14","author":"Rha","year":"2021","journal-title":"Appl. Clin. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109255_bb0410","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/ijms21020489","article-title":"Pharmacological chaperones: a therapeutic approach for diseases caused by destabilizing missense mutations","volume":"21","author":"Liguori","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109255_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065819","article-title":"Pharmacological chaperones and protein conformational diseases: approaches of computational structural biology","volume":"24","author":"Grasso","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:50:29Z","timestamp":1769716229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225002471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1096719225002471"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109255","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucopolysaccharidosis VI: Therapeutic strategies and perspectives","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109255"}}